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Abstract
We highlight the main developments that have been published during the first semester of the last year in the
Italian Journal of Pediatrics. We have carefully chosen information from numerous exciting progresses issued in the
Journal in the field of allergy, endocrinology, gastroenterology, neonatology, nutrition, nephrology, neurology,
public health, respiratory diseases and rheumatic diseases. The impact on the care of patients has been placed in
the broader context of studies that appeared in other journals. We think that many observations can be used
directly to upgrade management of patients.
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Background
This paper summarizes main advances that were reported
in the field of allergy, endocrinology, gastroenterology,
neonatology, nutrition, nephrology, neurology, public
health, respiratory diseases and rheumatology over the first
semester of 2019 in the Italian Journal of Pediatrics. The
most accessed papers have been carefully selected and put
in the context of studies that appeared in other journals.
Review
Allergy. 1-food allergy; 2-severe asthma; 3-vernal
Keratoconjunctivitis
There is a continuous effort to improve the management of
allergic diseases. Pathophysiology of food allergy is IgE-
mediated, non IgE-mediated (cell-mediated), or mixed (IgE
and cell-mediated). Manifestations of IgE-mediated reac-
tions include rhinoconjunctivitis, asthma, rash, angioedema,
urticaria, nausea, vomiting, abdominal pain, diarrhea, ana-
phylaxis. Trigger food is identified by medical history, IgE
tests (skin prick tests and/or serum specific IgE antibodies)
and oral food challenge that is the gold standard [1]. Avoid-
ance of culprit food is the cornerstone of food allergy treat-
ment. Oral immunotherapy (OIT) to cow’s milk, hen’s egg
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or peanut allergy is promising. However, it has been shown
that OIT is not able to induce total or partial food tolerance
in about 30% of children. Furthermore, the frequency of ad-
verse events is high and duration of effectiveness unclear.
Crisafulli G et al. [2] investigated the efficacy of add-on
therapy with omalizumab a monoclonal anti-IgE antibody
during OIT in 5 children with cow’s milk allergy. A com-
bination treatment (OIT plus omalizumab) preceded by a
pretreatment with omalizumab in 3 cases, was beneficial in
most children and tolerability was good. Omalizumab is
that has been approved for the treatment of severe persist-
ent allergic uncontrolled asthma and spontaneous chronic
urticaria. It has also been shown to be successful in chronic
rhinosinusitis [2, 3]. Among allergies with a mixed (IgE and
cell-mediated) pathophysiology, omalizumab could be
helpful in improving atopic dermatitis [4] that shares with
asthma, inflammatory mediators [5] and the response to
allergen immunotherapy [6] but it did not improve eosino-
philic esophagitis [2].
In asthmatic children, the prevention of recurrent
symptoms is based on long-term therapy and avoidance
of triggering factors including aeroallergens, food aller-
gens [7], physical exercise, passive smoking, pollutants.
Asthma control has been shown to be enhanced by
communication interventions. However, almost all the
asthmatic children are not enough engaged in discus-
sions on management [8]. The SOUND project pub-
lished a consensus for improving the communication to
children and adolescents with severe asthma and their
parents [9]. Recommendations are given to physicians
on how welcome they have made children and parents.
The knowledge of the context would be facilitated by
asking questions on goal of the visit, daily life (diet,
physical activity, relation with family members and
school advancement), by understanding the view of the
child, and by using child’s drawings to recognize his
thoughts. Advices are given on management of emo-
tions, and on how keeping relationships between the
visits. It is recommended to avoid prohibitions since
they can cause suffering and undesirably disturb the
relationship.
Vernal keratoconjunctivitis (VKC) is an underestimate
severe seasonal chronic inflammation that can lead to
persistent damages [10]. A systematic review [11] has
addressed the definition of diagnostic criteria and scor-
ing system. A lack of standards for diagnosis was found.
This mainly hampers the differentiation from seasonal
allergic conjunctivitis that is often due to grass pollens
[12]. This is even more difficult since VKC can coexist
with sensitization to seasonal pollens. Furthermore, a
great variation in clinical score have been showed. So,
continue efforts are needed by the scientific community
to have a common language on diagnostic criteria,
management and treatment. It is also advisable the
development of homogeneous scoring system to be rou-
tinely used.
Endocrinology. 1- growth in preterm infants; 2- syndrome
of inappropriate secretion of antidiuretic hormone; 3-
adrenal hemorrhage; 4- type 1 diabetes
Since early postnatal growth of preterm infants is an
important clue in clinical setting, Zhang et al. [13] studied
the postnatal growth patterns in a sample of Chinese
healthy late preterm infants. Until they reached a term
corrected age. Through bivariate, multivariate linear
regression analyses and final stepwise regression models,
interesting characteristics of postnatal growth have been
assessed. Among the most relevant emerge; an extremely
low rate (3%) of weight catch down growth, a prevalent
weight (46.2%) vs length (30.7%) catch up growth, a faster
postnatal weight and length catch up growth in males
versus females, as well as in twins versus singletons, a
superior weight growth in SGA and AGA versus LGA
infants, and a faster length growth velocity in infants of 36
versus 34 and 35weeks PMA at birth. The results of this
study show a better global postnatal growth pattern in late
preterm infants than previously described [14–16]. Thus,
the authors underline the necessity to consider in follow-
up studies the difference in feeding and adopted nutrition
strategies, as well as regional, local, ethical and traditional
factors that can contribute to the divergence in postnatal
growth patterns [16].
The acronym SIADH (syndrome of inappropriate secre-
tion of antidiuretic hormone) indicates a non-physiological
secretion of ADH as it occurs independently from effective
serum osmolality or circulating blood volume that nor-
mally regulates it. ADH stimulates water reabsorption
through binding to V2 receptors located in the renal tu-
bules, which mediates the concentration of urine, with
relative water excess in plasma leading to hyponatremia.
Inappropriate antidiuresis may also result from a gain-of-
function mutation in its type 2 receptor. Therefore, some
Authors prefer to use the term “syndrome of inappropriate
antidiuresis (SIAD)” including both situations. SIADH [17]
can be idiopathic or due to multiple causes (neurological,
pulmonary, malignant diseases, medications, acute condi-
tions as stress, pain, general anesthesia) because various
non-osmotic stimuli may cause AVP release. The classic
criteria for diagnosis are those found in the clinical case
described by Pintaldi et al. [18] (hyponatremia, high urinary
osmolarity, high urinary sodium concentration, absence of
edema or clinical signs of volume depletion). However, it is
important to remember that the diagnosis of SIADH re-
quires a normal renal, cardiac, hepatic, adrenal and thyroid
function [19]. In other words, it is a diagnosis of exclusion,
[20] In particular, hypothyroidism (extremely rare) and
adrenal insufficiency (AI) must be excluded. AI may be
due to ACTH/CRH insufficiency (secondary and tertiary
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form particularly important in patients who present with
neurosurgical conditions, such as traumatic brain injury,
subarachnoid hemorrhage and intracranial tumors) or due
to a primitive alteration of the adrenal gland which could
be congenital or acquired [21, 22]. In fact, in the above
mentioned clinical case [18] the analysis of the functional
parameters of the ACTH / Cortisol axis led to change the
initial diagnosis to the final one of an autoimmune adrena-
litis (Addison’s disease) which is considered,after the
congenital adrenal hyperplasia (CAH), the second more
frequent cause of primary AI. Finally, it is interesting to
underline the similarities of the case described by Pintaldi
[18] with others reported in Literature [23]. In particular,
the initial normality of the values of potassium which
would be assumed to be high in case of adrenal insuffi-
ciency but which were normal, probably due to the vomit-
ing presented by the patients and in addition, the presence
of some slight hyperpigmentation of the skin creases and
gingival pigmentations which may be useful for diagnostic
orientation during clinical evaluation.
Neonatal adrenal hemorrhage (NAH) is uncommon
(0.2–0.55%) [24]. In most cases is asymptomatic and
death is rare [25]. Ultrasonographic examination is com-
monly performed since it is immediate, accurate and safe
[26]. In NAH, according to pathological anatomical evo-
lution, temporal modification of echostructure is highly
specific. The hemorrhagic adrenal gland is enlarged and
homogeneously hyperechoic in newborns. Subsequently,
the lysis of the clot increases hypoechoic structure and
after 1 or 2 weeks cystic-colliquative feature emerges.
Sometimes, shell calcification then appears [27]. An
involuted complex structure small mass, partly calcified
without vascularization can residue. NAH can regress
without relics in a period ranging from 20 days to 5–6
months. Most neonatal supra-renal masses are identified
as congenital neuroblastoma (NBL) or adrenal hemorrhage
[28]. The histologic examination of tumor tissue or blood
marrow besides elevated levels of catecholamine metabo-
lites in urine or serum, is necessary for diagnosis of NBL.
Ultrasonographic examination may be useful in assessing
adrenal NBL. NBL may appear as a defined small mass
within the adrenal gland or an infiltrative complex mass,
lobulated with hemorrhagic zones. It is often solid, occa-
sionally with calcific punctate areas in newborns [29]. In
NAH, the calcification appears generally later. Ultrasonog-
raphy differentiation between cystic NAH and cystic NBL
may be difficult, especially when catecholamine metabolite
values are low. Color Doppler ultrasound examination
seems to have most significance in providing a correct
diagnosis. In NAH, a nonvascular flow and a regression of
lesion over time are observed [30]. In NBL, blood supply is
essential for its own growth. This tumor gives rise to char-
acteristic high velocity Doppler shifts. The usual follow-up
time for the resolution of the hemorrhage should be within
90 days. NBL should be suspected if the mass does not
resolve in 3months. Adrenal NBL often spontaneously
resolve. Therefore, a watchful waiting rather than an inter-
ventional approach is suggested [31]. Hypophosphatemia
can be one of the consequences of diabetic acidosis (DKA).
In most cases of DKA the decrease in blood levels of phos-
phates is mild, it is not considered responsible for specific
pathologies and it does not require correction as various
prospective studies have shown no clinical benefit. Phos-
phate replacement is instead indicated in the severe forms
(blood phosphate levels < 1mg /dL/0.32mmol / L) with
the appearance of symptoms [32]. They can in fact be
responsible for clinical manifestations mainly respiratory,
neuromuscular, cardiac and hematologic [33]. As regards
the cardiac involvement and in particular the arrhythmias,
there are no precise epidemiological data but, on the basis
of recent patient series, they appear infrequent compared
to other complications [34]. In that context, the clinical
case described by Miszczuk et al. [35] is an interesting one
in particular in two respects: 1) ventricular bigeminy and
trigeminy have not been previously described among
arrhythmias and although their origin may be multifactor-
ial the fact that they disappear with the phosphate supple-
mentation indicates an important pathogenetic role; 2) the
patient studied had blood levels of phosphate slightly
higher than the limit considered diagnostic for severe
forms, but a set of elements rightly suggest that an intracel-
lular phosphate depletion had been created in the body. In
other words, the intracellular phosphate level is primarily
responsible for clinical manifestations. Concerning clinical
practice, the recent ISPAD consensus concludes: “although
administration of phosphate is associated with a risk of
hypocalcemia, an IV solution that contains a 50:50 mixture
of potassium phosphate and another suitable potassium
salt (potassium chloride or potassium acetate), generally
permits adequate phosphate replacement while avoiding
clinically significant hypocalcemia.”
Mauriac’s syndrome (MS) was initially described in
1930 and it is being characterized by growth failure,
delayed puberty, cushingoid appearance, hepatomegaly
with abnormal liver enzymes, and hypercholesterolemia.
Such a syndrome has been mainly reported in brittle
type 1 diabetes (DM1) and very rarely in DM2. In the
last few decades, the improvement of diabetes therapy
(education, use of insulin and /or its analogues and
delivery technology) may have suggested that MS was
about the past in the history of diabetes. On the con-
trary, the most recent reviews in Literature tell us that
MS still exists especially in adolescent who do not
always accept the rules that a good control of diabetes
requires and in patients who live in socially and culturally
backward environments where there may be objective dif-
ficulties in managing the disease [36]. On the other hand,
it should be kept in mind that the hepatomegaly (due to
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an overloading of hepatocytes with glycogen) represents
one of the major signs of MS and it may be the only
feature present both in children / adolescents and in
adults. It has been defined in various ways: liver glycogen
storage, hepatic or liver glycogenosis, DM-associated
glycogen storage hepatomegaly and lately “glycogenic
hepatopathy” (GH). Real incidence and prevalence of GH
are unknown, commonly being misdiagnosed or under-
diagnosed [37]. However, if we consider some series of
patients, we find that about 10% of diabetic children had
hepatic hyperechogeneity decreasing after a period of
several months of better adherence to therapy [38]. In
other words, hepatomegaly does not seem as rare as
generally thought and should be sought in the follow up
of diabetic patients. When present, the blood level of
transaminases should be assessed, and other causes of
liver disease excluded. If there is still a diagnostic doubt,
liver biopsy is the gold standard. According to some AA,
it would be useful above all to differentiate liver
glycogen storage from nonalcoholic fatty liver disease
(NAFLD), considering that the former is generally
transient and with a benign prognosis while the latter
(much more frequent in DM2) can evolve towards
forms of cirrhosis and cancer [39, 40].
Global and public health. 1-violence
Violence against children, adolescent and young adults
shows, all over the world, a dramatic and still unsolved
concern for the health, the connected social and legal
problems. Globally it is estimated that up to1 billion
children aged 2–17 years, have experienced physical,
sexual, or emotional violence or neglect in one year (as
cited in [41] and that in the WHO European Region
violence affects over 55 million victims [42]. That can
occur in various forms [41]. In Europe we consider prev-
alences from 9.6% for sexual abuse, 16.3% for physical
neglect, 18.4% for emotional neglect, and 2.9% for phys-
ical abuse, to 29.6% for emotional abuse [42]. We must
also keep in mind that the general prevalence is often
underestimated due to the difficulty in various States for
fully collecting data. Numerous studies have then
highlighted the long-term consequences of the violence
suffered. The victims are in fact at greater risk of devel-
oping both chronic diseases and behavioural and rela-
tional alterations [43]. There are many factors that can
facilitate violence both at an individual level (such as
lower levels of education, low income, having a disability
or mental health problems) and at community level
(such as settings with weak governance and poor law
enforcement) and with many of such it is possible to act
with an appropriate prevention aimed in particular at
family and school which are known to be the places
where maltreatment occurs most frequently. On the
other hand, the importance of prevention has been
considered a priority by WHO which in connection with
other international agencies has recently proposed the
INSPIRE program (www.who.int › inspire-package)
based on seven strategies towards reducing and eliminat-
ing violence against children. With regard to the school
environment in particular, many studies and resulting
preventive recommendations have taken into consider-
ation bullying or cyberbullying phenomena which are
certainly the most frequent. On the basis of the data
collected in Italy by Ferrara et al. [41] and of a recent
review of the international literature [44], it is useful to
point out that studies about the violent teacher-student
relationship are very rare and that this phenomenon,
certainly less frequent than the previous one, would
deserve greater attention both at the epidemiological
level and for establishing setting methods and action to
prevent that.
Neonatology. 1-preterm birth; 2-infant mortality; 3-
vitamin K deficiency; 4-Lotus birth
Preterm birth is a public health concern and it repre-
sents the leading cause of neonatal mortality [45].
Preterm newborns also present neurological impairment,
respiratory, renal and gastrointestinal complications. All
these conditions may seriously affect the neurocognitive
outcome and cause severe disability. The highest mortal-
ity rates of preterm birth have been found in developing
countries [46]. In an observational study conducted in
Ethiopia, the mortality rate of preterm newborns was
28.8% [47]. Neonatal deaths occurred within the first 24
h in 11.4% of cases and within the first 7 days in 85.23%
of instances. Perinatal asphyxia was the major cause of
death followed by hyaline membrane disease, jaundice,
clinical sepsis and apnoea. Griffin et al. [48] proposed a
model for reducing preterm mortality based on WHO
recommendations. He pointed out that combined inter-
ventions lead to the greatest impact on preterm mortal-
ity. The most effective single interventions are oxygen/
CPAP, cord care, breastfeeding, and antibiotics. New
efforts are needed to prompt identify potential preterm
births in order to provide a proper intervention. Granese
R et al. [49] found that vaginal/urinary infections, under-
weight, obesity, unmarried status, uterine anomalies,
poly/oligohydramnios, hypertension, diabetes, a history
of preterm birth and a short cervix length in the second
trimester were the main risk factors for preterm birth.
Of note, a short cervix predicted early preterm and very
early preterm delivery while the other factors should be
considered in late preterm cases. This study indicates
that cervix length evaluation [50] during the midtrime-
ster should be performed not only in women at high risk
of preterm birth but in all cases since it may early detect
high-risk pregnancies and guarantee progesterone ad-
ministration [51] that diminishes the risk of preterm
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birth and reduces neonatal morbidity. Socioeconomical
factors and health development play a role in the neo-
natal mortality. In Italy, the overall neonatal mortality
rate is 2 per one thousand live births, that is one of the
lowest infant mortality rates of all countries. However,
there still are differences among areas of the country
(North-Centre-South) that should be linked to inad-
equate care level and organization of perinatal care [52].
Of note, mortality index among immigrants were higher
than among Italians. Accordingly, in England ethnic
minority newborns had twice risk of adverse events at
birth than British infants [53]. Several explanations may
be offered to explain these findings. This could be asso-
ciated with socioeconomical conditions. Language and
cultural differences between minority and majority
groups can create barriers to access or benefit from in-
formation. Newborns, whose parents have a low level of
education, are more likely to die in early life [54]. The
late onset type of vitamin K deficiency can occur with
cerebral haemorrhage. Ceratto and Savino [55] reported
a healthy newborn who developed intracranial bleeding
due to vitamin K deficiency at the end of the first week
of life. She received oral vitamin K at birth because she
had no risk factor. These findings can suggest that intra-
muscular vitamin K may be useful for all newborns
because of unpredictable risk factors at birth (malabsorp-
tion or cholestasis) other than preterm birth [56]. The
American Academy of Pediatrics, the Canadian Pediatric
Society [57] and the ESPGHAN Committee on Nutrition
[58] recommend the intramuscular administration of the
first dose of vitamin K at birth since it would be linked
with less failure mainly for late bleeding than oral route
administration, due to minor abnormalities of absorption
[59]. In many countries, national recommendations on
this issue are lacking. There is a need of consistent indica-
tions about optimal dose and routes of administration of
vitamin K prophylaxis in newborns. Lotus birth is the
practice of umbilical nonseverance, leaving the umbilical
cord and the placenta intact and attached until it detaches
spontaneously after 3–10 days. Meanwhile, the placenta is
put in a bowl with salt and herbs [60]. Clinical risks,
bioethical and medico legal aspects of this controversial
procedure have been analysed by Bonsignore et al. [61].
From the health side, studies about this particular practice
are inconsistent, of poor quality and with small sample.
There is no clear evidence that having placenta connected
to the baby for many days provides benefits to him/her.
On the other hand, there is a potential risk for reduced
neonatal perfusion and clot formation. In a recent case
report series, no infections occurred after lotus birth and
mothers expressed interest in repeat lotus birth in the
future [62]. However, the dead tissue attached to the
newborn may be affected by bacteria and possible compli-
cations related to this practice such as omphalitis or other
infections have been described [63]. From the medico-
legal side, the question arises whether placenta belongs to
the mother or to the baby and no clear statement assess
the juridical availability of placenta. Therefore, when the
mother requests the placenta, she should be allowed to
have it, unless a public health issue arises. Families should
be adequately updated about the risk/benefit ratio of
Lotus birth and informed forms should be used. Overall,
Bonsignore et al. [61] consider Lotus birth inadvisable
from both medical and rational point of view.
Nutrition. 1-vitamin D; 2-malnutrition
Vitamin D subclinical deficiency or insufficiency continue
to be a common finding [64, 65]. Vitamin D is useful for
bone health and it has been investigated for preventing
cancer, cardiovascular disease, type 2 diabetes mellitus,
neurologic disorders, autoimmune disorders, infectious
disease also by increasing the function of gastrointestinal
microbiota [66] which may have a role in preventing infec-
tious diseases [67]. Vitamin D supplementation is a matter
of debate. It is usually recommended when children have
risk factors for deficiency of vitamin D [64] such as inad-
equate intake, limited skin exposure to sunlight, dark skin,
malabsorption, drug intake (anticonvulsants, systemic
glucocorticoids, antiretroviral therapy), liver or kidney
diseases, obesity). In Italy, the recommended supplementa-
tion in children from 1 to 17 years is 600–1000 IU/day
vitamin D3 and children with risk factors should receive
1000–1500/UI vitamin D3 per day [64]. To prevent the
deficiency of vitamin D, it was conducted a study on the
effect of vitamin D3 1500 IU/day [65] from November to
April versus no supplementation [64]. In the intervention
group, there was no side effect and the 25-hydroxyvitamin
D maximum serum level was 71 ng/ml. In adolescents with
vitamin D insufficiency, there was only a slight increase in
mean 25-hydroxyvitamin D serum level so it is possible that
this age range would receive a higher dose of vitamin D3.
No consensus has been reached about the period of the
administration of vitamin D supplementation [68]. In this
study, the intervention group had normal serum value of
25-hydroxyvitamin D all the year except in May. In the
control group vitamin D deficiency were found in 4months
out of 6 at the beginning of the year and vitamin D insuffi-
ciency in the other 2months. So, it would be reasonable to
extend vitamin D supplementation.
Undernutrition is still a leading cause of morbidity and
mortality in children and in some developing countries.
Both acute and chronic forms (wasting and stunting)
represent a public health challenge. They are strongly
inversely correlated with the wealth of nations. In Sub-
Saharan Africa [69] and in South Asia [70], risk factors
for wasting and stunting in children are low birth
weight, low mother’s BMI, small birth size, low parental
education, young mother, increasing child’s age, male,
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inadequate food supply, unhealthy living environments.
In the slums of Nairobi (Kenia), 26.30% of children
under 12 months of age was stunted, 6.3% wasted and
13.16% underweight [71]. Wasting was more frequently
associated with infectious diseases such as cough and
rapid breathing and diarrhea, probably due to the acute
loss of weight. Regarding mortality, it has been estimated
that 45% of deaths in children under 5 years of age in
the world is due to undernutrition [72]. Mid-upper arm
circumference (MUAC) and weight-for-height/length Z-
score (WHZ) are used to identify children with severe
acute malnutrition (SAM) but they are affected by
gender, region and age bias [73]. Therefore, the burden
of SAM can be higher than that reported. Moreover,
SAM is a risk factor for growth retardation and impaired
psychosocial and cognitive development. Fikrie et al. [74]
studied Ethiopian hospitalized children with malnutrition
assessed by mid-upper arm circumference (MUAC),
weight-for-height/length Z-score (WHZ), edema. All chil-
dren presented co-morbidities, including pneumonia, diar-
rhea, anaemia, tuberculosis. They found that the recovery
rate was 69.4%, which was below the minimum accepted
international standard of 75% [75] and the mortality rate
was 10%. Weight gain and length of staying were in line
with the international standard and Ethiopian protocol for
management of SAM. These results are concordant with
those of a similar research conducted in Northwest
Ethiopia [76]. Comorbidities in the enrolled population
may elucidate the low recovery rate [76]. Other explana-
tions may be related to therapeutic milk intake and high
rates of mortality. Finally, relapse after discharge was 7.1%
of all cases. This highlights that standardized protocols for
SAM follow-up after discharge are always needed.
Nephrology. 1-congenital anomalies; 2-
Hypophosphatemic rickets
Congenital anomalies of the kidney and urinary tract
(CAKUTs) include structural and functional abnormalities
of the kidney, collecting system, bladder, and urethral
abnormalities, and are some of the most common birth
defects in newborns. Li and collaborators conducted a
retrospective study in China’s Zhejiang Province, includ-
ing all births and all ascertained patients with CAKUTs
registered from 2010 to 2016. There were enrolled 2790
patients identified among 1,748,038 births [77]. Authors
observed that males (OR 1.28, 95% CI 1.18–1.38), multiple
births (OR 1.53, 95% CI 1.21–1.92) and births in urban
areas (OR 1.27, 95% CI 1.18–1.37) presented a higher risk
of CAKUTs. Instead, CAKUTs were poorly associated
with maternal age. Overall, 22.69% of births with CAKUTs
had associated malformations, especially heart defects.
The most frequent CAKUT was hydronephrosis, (31.79%),
followed by polycystic kidney, renal agenesis, renal ecto-
pia, and renal duplication. In this study, the prevalence of
CAKUTs was much lower than in reports from
Copenhagen, Russia, and western areas of Saudi Arabia,
maybe explained by differences in sociodemographic
background, malformation inclusion criteria. In Mur-
mansk County, a population-based birth registry recorded
anomalies diagnosed from 22weeks of gestation to hos-
pital discharge [78]. Those authors admitted that some
figures had been overestimated owing to the lack of strict
diagnostic criteria for pyelectasis, hydronephrosis, and un-
specified anomalies [78]. In Saudi Arabia, the high rate of
consanguineous marriage within the local population
might increase the rate of CAKUTs [79]. The study in
Denmark followed up a birth cohort for 8 years [80].
Finally, the authors evaluated that the prevalence of
CAKUTs doubled from 2010 to 2016, which might be
owing to increased screening, developments in ultrasound
technology, and improved birth defect surveillance. X-
linked hypophosphatemic rickets (XLH) is a rare disease
caused by mutations in the PHEX gene, this disease is
poorly known, and diagnosis is frequently delayed. Emma
et al. collected data by means of a questionnaire on XLH
epidemiology, diagnosis and treatment, from 10 Italian
centres on 175 patients, followed between 1998 and 2017
[81]. The diagnosis was made before the age of 1 and
between 1 and 5 years in 11 and 50% of cases, respectively.
Clinically apparent bone deformities were present in 95%
of patients. Other frequent complications included bone
pain (40%), dental abscesses (33%), and dental malposi-
tions (53%). Treatment protocols varied substantially
among centres. Nephrocalcinosis, a complication of
conventional treatment, was observed in 34% of patients.
Tertiary hyperparathyroidism developed in 6% of patients.
Overall, nephrocalcinosis has been reported in the litera-
ture in 30–70% of patients [82–84]. The present study
was conducted to evaluate the current status in the diag-
nosis and treatment of XLH in Italy. Overall, results are in
line with available data in the literature, although with
some noticeable differences. The prevalence of XLH is
estimated between 1.2–3.0/60,000 [82]. In this survey the
number is lower than expected, indicating that the disease
is either underdiagnosed.
Neurology. 1-PANDAS syndrome; 2-headache
Guido et al. showed the successful results of the eye
movement desensitisation and reprocessing (EMDR)
therapy associated with parent management training
(PMT) in a 11-year-old boy who presented with simple
and complex vocal tics, motor tics, obsessive-compulsive
traits and irritability from the age of 6 years, diagnosed
as paediatric autoimmune neuropsychiatric disorder
associated with streptococcus (PANDAS) [85]. These
results indicate the possibility of improving the treatment
outcomes of patients with PANDAS by a combined
approach using both antibiotic and EMDR therapies.
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According to the most recent guidelines [86], elective
evidence-based therapies for the treatment of PANDAS
include Cognitive Behavioural Therapy, parent training and
drug therapy. EMDR therapy had never been utilised before
in patients with PANDAS syndrome [87], this method
works on the present and not on the past. The explanatory
model underlying these considerations is the Adaptive
Information Processing model, in which previously stored
dysfunctionally without proper assimilation within of a
wider adaptive network present in the patient [88].
Migraine is one of the most prevalent chronic pain
manifestations of childhood, affecting up to 10% of chil-
dren between the ages of 5 and 15 years and up to 28%
of adolescents aged from 15 to 19 years [89]. Moreover,
parents are often concerned about chronic therapies and
even clinicians prefer to avoid prescription of prophylac-
tic therapies in children, due to the poor evidence of
efficacy and significant potential adverse effects in this
population [90]. Moscano et al. conducted an observa-
tional multicenter study performed in 91 children with
migraine, with (MO) or without aura (MA), or tension-
type headache (TTH) [91]. A fixed-dose of Partena®
tablets (a combination of Mg2+ 169mg, CoQ10 20 mg,
VitB2 4,8 mg, Feverfew 150mg-1,2 mg Parthenolides and
Andrographis paniculata 100 mg), was administered for
16 weeks. The herbal supplement significantly reduced
the frequency of headaches in TTH patients during
treatment period, maintaining the efficacy after 16 weeks
of treatment withdrawal. A significant effect was observed
also in the MO and MA groups during treatment. These
results are according several epidemiologic, preclinical
and clinical evidence supporting the usefulness of other
active principles of Partena® in prophylactic treatment of
migraine currently available in Europe and USA as dietary
supplements [92]. The most recent randomized controlled
trial, using a stable extract, add some positive evidence
about the efficacy of in the prophylactic treatment of
migraine [92]. Studies on Feverfew efficacy in children
and adolescents with migraine are lacking.
Gastroenterology. 1-celiac disease; 2-Alagille syndrome
An increased prevalence of celiac disease (CD) has been
observed in several cohorts of cystic fibrosis (CF) patients.
A recent study indicates that the gluten/gliadin-derived
peptide (P31–43) can cause the cystic fibrosis transmem-
brane conductance regulator (CFTR) channel protein
inhibition in intestinal epithelial cells, thus causing a local
stress response that contributes to the immunopathology of
CD. Mauri et al. speculated that P31–43-induced CFTR
inhibition elicits the danger signals that ignite the epithelial
stress response and perturb epithelial proteostasis [93].
Importantly, potentiators of CFTR channel gating, such as
the FDA-approved drug Ivacaftor, prevent P31–43 driven
CFTR inhibition and suppress the gliadin-induced stress
response in cells from celiac patients, as well as the
immunopathology developing in gliadin-sensitive mice.
Altogether these findings demonstrate that gliadin in-
duced CFTR malfunction is at the apex of the patho-
genic cascade leading to CD [94, 95]. Paucity of
interlobular bile ducts is an important observation at
liver biopsy in the diagnostic work-up of neonatal cho-
lestasis. To date, other than in the Alagille syndrome,
syndromic paucity of interlobular bile ducts has been
documented in four cholestatic neonates with HFN1β
mutations. A syndromic phenotype, known as renal
cysts and diabetes syndrome (RCAD), has been identi-
fied. Pinon et al. reported a novel case of 5-week-old
boy affected by paucity of interlobular bile ducts due to
an HFN1β defect [96]. He was admitted for cholestatic
jaundice with increased gamma-glutamyl transpeptidase
and an unremarkable clinical examination, character-
ized by cholestatic disease, hyperechogenic kidneys with
multiple bilateral cortical cysts at ultrasound examin-
ation, associated with moderately impaired renal func-
tion with proteinuria, polyuria and metabolic acidosis,
paucity of interlobular bile ducts at liver biopsy, thus
the diagnosis of Alagille syndrome (AGS) was considered,
but excluded. Although genetic tests for liver cholestatic
diseases were performed with negative results for Alagille
syndrome (JAG1 and NOTCH2), a de-novo missense mu-
tation of HNF1β gene was detected. To date, only others 5
cases of neonatal cholestasis are reported in literature as
associated to HNF1β mutations, in most cases de-novo
deletions, with similar clinical course [97–100]. HFN1β
defects should be considered in neonates with cholestasis
and renal impairment, especially in SGA and IUGR new-
borns with a family history of renal disease or diabetes, in
addition to AGS.
Respiratory diseases. 1- recurrent wheezing; 2-
Bronchopulmonary dysplasia; 3- cystic fibrosis
Recurrent wheezing and/or asthma are common chronic
respiratory disease in children. Studies have demon-
strated that children hospitalized for RSV bronchiolitis
during infancy were more likely to have subsequent epi-
sodes of wheezing [101]. Also, eosinophil-derived neuro-
toxin (EDN), contained in eosinophil cytotoxic granule
proteins has been considered to be involved in the re-
current wheezing and asthma development in later life
[102]. Zhai et al. followed-up for 1-year 145 children of
3 years old or younger, who were hospitalized with
wheezing, in order to analyse factors that may predict
recurrent wheezing [103]. The authors demonstrated
that eczema, respiratory syncytial virus (RSV) infection,
eosinophil count and eosinophil-derived neurotoxin
(EDN) concentration were all risk factors related to re-
current wheezing, speculating that the combination of
eosinophil count and serum EDN quantification may be
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served as one of the biomarkers to predict the recurrent
wheezing in clinical practice. This data are confirmed by
a double-blind randomized, placebo-controlled study,
where the parallel comparison of montelukast and
placebo administered for 3 months in 200 infants (age,
6–24 months), who were hospitalized with their first epi-
sode of acute RSV bronchiolitis, showed that serum
EDN levels correlated significantly with the total number
of wheezing episodes at 12 months in both groups of
treated with placebo or leukotriene receptor antagonist
[104]. There are not standard criteria for weaning from
continuous positive airways pressure (CPAP) and/or
oxygen therapy the premature babies. Vento et al.
wanted to verify if a physiologic test, modified respect to
that developed by Walsh and collaborators for estimat-
ing bronchopulmonary dysplasia (BPD) rate, can be used
as a clinical tool for weaning the premature babies from
CPAP and/or oxygen therapy [105, 106]. They tested 23
neonates with body weight (BW) 500–1250 g and gesta-
tional age (GA) ≤ 32 weeks, receiving FiO2 ≤ 0.30 by hood
or CPAP, monitoring transcutaneous partial pressure of
CO2 (TcPCO2) and SpO2, at 28 days of life and at 36
weeks of postmenstrual age, in 3 steps: baseline, challenge
(FiO2 and CPAP reduction to room air) and post-test
(room air). Six of 23 tested babies (26%) passed the
challenge at 28 days of life, 4 of 10 tested babies (40%)
passed the challenge at 36 weeks. Median values of SpO2
were significantly higher in the neonates passing the test,
respect to the failing patients. At the same time median
values of TcPCO2 were significantly higher in the latter
babies. The authors speculated that TcPCO2 monitoring
appeared to be a new useful parameter for failure predic-
tion of weaning. These data are confirmed in a multicen-
tre study conducted by Kaempf et al., where pCO2 and
SpO2 values appears to be reasonably good markers of
lung injury, median pCO2 values were significantly higher
in infants with BPD compared to controls [107]. Vitamin
D plays an important role in inflammatory responses after
antigen exposure. T helper 17 cells produce Il-17A
promoted by Il-23 and bind it to its receptor on the T cell
membrane. They are both critical for neutrophil recruit-
ment in a chronic P. aeruginosa pulmonary infection
[108]. Olszowiec-Chlebna et al. [109]. conducted a ran-
domized, placebo-controlled, double-blind, cross-over trial
in 23 patients with cystic fibrosis (CF), chronically infected
by P. aeruginosa, and randomly assigned to calcitriol or
cholecalciferol groups. The results showed that both ana-
logs of vitamin D revealed their anti-inflammatory effect,
reducing the level of Il-17A and Il-23 in the airway of CF
patients with chronic P. aeruginosa infection, and that
calcitriol improve calcium phosphorus metabolism after
supplementation without adverse effects. Pincikova et al.
randomized CF patients to receive 35,000–50,000 IU vita-
min D per week for 3 months and observed that this
supplementation has pleiotropic immunomodulatory
effects in CF in a dose-dependent manner, demonstrated
that free serum 25 OH D level correlated positively with
anti-inflammatory soluble immunological parameters
[110]. Instead, Olszowiec-Chlebna et al. did not observe
any statistically significant changes of 25OHD serum level
due to the supplementation with cholecalciferol 1000 IU
per day. This is probably related to low dose of adminis-
tered cholecalciferol.
Rheumatic diseases
Thrombotic thrombocytopenic purpura (TTP) is a dis-
order of the blood-coagulation system. Although TTP in
patients with systemic lupus erythematosis (SLE) is rare,
TTP-SLE has high mortality, ranging from 34 to 62.5%
[111]. TTP-SLE is related to endothelial injury or platelet
aggregation that lead to vascular injury or autoimmune
response. Li et al. want to report the clinical features of
patients with TTP-SLE and enrolled 25 paediatric patients
(median age 14 years old) [112]. They observed that all
patients had decreased platelet count and microangio-
pathic haemolytic anemia. Fever, rash, edema and neuro-
logical symptoms were the main clinical symptoms.
Nineteen patients (76%) had impaired renal function, with
a lupus nephritis class IV (20%) and thrombotic microangi-
opathy (20%) at renal biopsy, in line with the observations
in adult TTP-SLE patients [113]. Thirteen patients (52%)
were treated with glucocorticoids in combination with im-
munosuppressive agent, and 10 patients (40%) were treated
with plasma exchange combined with glucocorticoids plus
immunosuppressive agent. One patient died due to lung
infection; others had disease remission. These data showed
that TTP-SLE often had a moderate to severe lupus disease
activity, as confirmed in literature [114]. Testing of LDH
level and blood smear should be performed when kidney
and neurological symptoms arise in children with SLE. The
use of combination therapy, glucocorticoids plus immuno-
suppressive agent, provided satisfactory clinical outcome.
Patients with refractory TTP-SLE will also need plasma
exchange therapy.
Conclusions
The first semester of year 2019 was a remarkable time in
the field of paediatrics. We have described developments
that have improved our knowledge across many areas.
They covered mechanisms and clinical management of
diseases. We look forward to additional thought-
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